Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21098782 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL22203223 | 0.85 | ALDH1A1 (0.62) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL13679347 | 0.83 | LMNA (0.46) | ALDH1A1TDP1LMNACACNA2D1CACNB3 | |
| SCHEMBL20460829 | 0.83 | ALDH1A1 (0.60) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL20124078 | 0.82 | ALDH1A1 (0.65) | ALDH1A1TDP1LMNACACNA2D1CACNB3 | |
| SCHEMBL21093304 | 0.81 | ALDH1A1 (0.64) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL20673516 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL23530054 | 0.80 | ALDH1A1 (0.62) | ALDH1A1TDP1LMNACYP3A4TSHR | |
| SCHEMBL17613188 | 0.79 | ALDH1A1 (0.75) | ALDH1A1TDP1CYP3A4TSHR | |
| SCHEMBL29068750 | 0.79 | LMNA (0.36) | ALDH1A1TDP1LMNACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885TDP1 236/4885LMNA 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.